• FDA approves Enhertu for HER2-low breast cancer

    12 days ago - By Healio

    The FDA approved fam-trastuzumab deruxtecan-nxki for treatment of certain patients with unresectable or metastatic HER2-low breast cancer.
    The approval - the first for a targeted therapy to treat HER2-low breast cancer - applies to patients who received prior chemotherapy in the metastatic setting, or those whose disease progressed during or within 6 months of adjuvant chemotherapy.
    Fam-trastuzumab deruxtecan is a novel antibody-drug conjugate with three components: a humanized anti-HER2 immunoglobulin G1 monoclonal antibody with the same amino
    Read more ...

     

  • FDA Okays First Targeted Agent for HER2-Low Breast Cancer

    FDA Okays First Targeted Agent for HER2-Low Breast Cancer

    12 days ago - By Medscape

    The targeted therapy led to longer progression-free and overall survival compared with chemotherapy.
    FDA Approvals
    Read more ...

     

  • FDA OKs First Targeted Drug for HER2-Low Breast Cancer

    FDA OKs First Targeted Drug for HER2-Low Breast Cancer

    12 days ago - By MedPageToday

    The FDA has approved the first targeted therapy for unresectable/metastatic breast cancer in the newly defined low-HER2 subtype.
    The approval for trastuzumab deruxtecan recognizes the recent expansion of the...
    Read more ...